These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11485619)

  • 21. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy.
    Imami N; Antonopoulos C; Hardy GA; Gazzard B; Gotch FM
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1499-508. PubMed ID: 10580400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART.
    Schüpbach J; Tomasik Z; Knuchel M; Opravil M; Günthard HF; Nadal D; Böni J; ;
    J Med Virol; 2006 Aug; 78(8):1003-10. PubMed ID: 16789014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.
    Sarmati L; Nicastri E; el-Sawaf G; Ventura L; Salanitro A; Ercoli L; Vella S; Andreoni M
    J Med Virol; 1997 Dec; 53(4):313-8. PubMed ID: 9407377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
    Angel JB; Parato KG; Kumar A; Kravcik S; Badley AD; Fex C; Ashby D; Sun E; Cameron DW
    J Infect Dis; 2001 Feb; 183(4):546-54. PubMed ID: 11170979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.
    Trkola A; Kuster H; Leemann C; Oxenius A; Fagard C; Furrer H; Battegay M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Bonhoeffer S; Günthard HF;
    Blood; 2004 Sep; 104(6):1784-92. PubMed ID: 15187026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures.
    La Sala GB; Pilotti E; Nicoli A; Pinelli S; Villani MT; Ronzi P; Zendri E; Re MC; Magnani G; Casoli C
    AIDS; 2007 Jan; 21(3):377-9. PubMed ID: 17255749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count.
    Forthal DN; Landucci G; Keenan B
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):553-61. PubMed ID: 11350669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption.
    Matsuda R; Boström AC; Fredriksson M; Fredriksson EL; Bratt G; Hejdeman B; Sandström E; Okuda K; Wahren B
    Microbiol Immunol; 2006; 50(8):629-35. PubMed ID: 16924148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.
    Montefiori DC; Altfeld M; Lee PK; Bilska M; Zhou J; Johnston MN; Gao F; Walker BD; Rosenberg ES
    J Immunol; 2003 Apr; 170(7):3906-14. PubMed ID: 12646660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1-infected individuals in antiretroviral therapy react specifically with polyfunctional T-cell responses to Gag p24.
    Brandt L; Benfield T; Kronborg G; Gerstoft J; Fomsgaard A; Karlsson I
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):418-27. PubMed ID: 23507659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
    Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
    Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.
    Bongertz V; Ouverney EP; Fernandez SC; Grinsztejn B; Veloso V; Couto-Fernandez JC; Pilotto JH; Morgado MG
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):817-25. PubMed ID: 18060317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.
    Binley JM; Klasse PJ; Cao Y; Jones I; Markowitz M; Ho DD; Moore JP
    J Virol; 1997 Apr; 71(4):2799-809. PubMed ID: 9060635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART.
    Patterson BK; McCallister S; Schutz M; Siegel JN; Shults K; Flener Z; Landay A
    AIDS; 2001 Sep; 15(13):1635-41. PubMed ID: 11546937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.